Laidlaw & Company (UK) Ltd. provides investment banking and wealth management services to institutions and individuals in the United States and the United Kingdom. Its investment banking services include capital raising through placement of equity with institutional and high net worth retail investors; placement of debt and mezzanine capital with institutional investors; acquisition financing; arrangement of national exchange listings; the United States trading markets; AIM-listed transactions in the United Kingdom market; and initial public offerings. The company’s investment banking services also comprise advisory services on acquisitions, divestitures, fairness opinions, financial restruc...
546 5th Avenue
New York, NY 10036
Relmada Therapeutics Announces Settlement of Legal Action with Laidlaw & Company (UK) Ltd
May 18 17
Relmada Therapeutics, Inc. and Laidlaw & Company (UK) Ltd. announced final disposition of all claims and counterclaims in all legal proceedings related to Relmada Therapeutics, Inc. v. Laidlaw & Company (UK) Ltd., et al., Case No.1:16-CV-07767, pending in the United States District Court for the Southern District of New York. On May 16, 2017, Relmada Therapeutics, Inc. entered into a confidential settlement agreement and release with Laidlaw & Company (UK) Ltd., James P. Ahern, and Matthew D. Eitner. Pursuant to the terms of the Agreement, all outstanding litigation between the parties was dismissed with prejudice, including all claims and counterclaims in all legal proceedings related to Relmada Therapeutics, Inc. v. Laidlaw & Company (UK) Ltd., et al., Case No.1:16-CV-07767, pending in the United States District Court for the Southern District of New York. Except for certain reimbursement of legal expenses to Laidlaw and its principals by the Company, none of the parties paid any monetary compensation to any other party in connection with the settlement of the matter. Laidlaw and its principals agreed to a lock-up prohibiting transfers or sales of their shares for one year and not to transfer more than 25% in any quarter of their shares in the subsequent twelve months. Laidlaw and its principals have also agreed to standstill commitments for two years, that includes, among other things, not to (i) nominate any person for election at any meeting of shareholders or make a request of the company to seek the resignation of any of its directors, (ii) submit any proposal for consideration at, or bring any other business before any meeting of the shareholders, (iii) seek to call a special meeting of the shareholders, and (iv) effect or seek to effect, or participate in (a) any acquisition of any material assets or businesses of the company, (b) any tender offer or exchange offer, merger, acquisition or other business combination involving the company, or (c) any recapitalization of the company.
Relmada Therapeutics, Inc. Files Amended Complaint Against Laidlaw & Company (UK) Ltd
Jan 26 16
Relmada Therapeutics Inc. announced that it has filed a motion to amend its complaint against Laidlaw &Company (UK) Ltd. (Laidlaw) in the U.S. District Court for the District of Nevada. The motion to file an amended complaint is part of the lawsuit that the company had previously filed in the Nevada District Court. The amended complaint includes an additional legal claim based on Laidlaw's breach of the fiduciary duty that it owed to Relmada when Laidlaw disclosed confidential information that it acquired in its capacity as the company's investment banker. Relmada is also seeking monetary damages arising from fees and costs that it incurred responding to Laidlaw's false and misleading proxy materials in December 2015. Relmada noted that the Nevada court previously issued a temporary restraining order and associated injunction against Laidlaw and its principals, Matthew Eitner and James Ahern, as a result of their dissemination of false and misleading proxy materials. Relmada's Board believes Laidlaw must compensate the Company for the damages it has suffered as a result of Laidlaw's actions, and that Laidlaw must be prevented from harming the company in the future.
Laidlaw & Company, LTD. Announces Executive Changes
Jan 12 16
Laidlaw & Company, LTD. announced the expansion of the London office with the addition of two team member: Richard Michalski, Senior Managing Director in Wealth Management and Bryan Kobel, Managing Director in Equity Capital Markets. The team will look to build on the current infrastructure and client base in the Wealth Management division and provide European healthcare companies and investors access to the US capital markets. Mr. Richard Michalski joined Laidlaw & Co. (Ltd) as Senior Managing Director in November 2010 from Aegis Capital, where he was a Senior Vice President. Mr. Bryan Kobel joined Laidlaw & Co. (Ltd) in March of 2012 from a small cap consulting company. Most recently, he was instrumental in helping to develop the US capital markets presence of Laidlaw & Co. since joining.